Advertisement

Clinical Journal of Gastroenterology

, Volume 9, Issue 2, pp 55–58 | Cite as

Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer

  • Takayuki Suzuki
  • Hideaki ShimadaEmail author
  • Mitsunori Ushigome
  • Junichi Koike
  • Kimihiko Funahashi
  • Tetsuo Nemoto
  • Hironori Kaneko
Case Report

Abstract

The overexpression of mutant p53 stimulates serum p53 antibody production in patients with colorectal carcinoma even in superficial tumors. Although the short-term perioperative monitoring of serum p53 antibody titers is reported to be useful in predicting tumor recurrence and patient survival in colorectal carcinoma, the clinical utility of the long-term monitoring of serum p53 antibody titers in patients with colorectal cancer remains unknown. Here, we report the 3-year monitoring of serum p53 antibody titers in a 60-year-old man with rectal cancer, clinical stage IV (T2N2M1b, lung and liver metastases), who was treated with chemotherapy and surgery. Screening tests for CEA (29.4 ng/ml), CA19-9 (41.1 U/ml), and serum p53 antibody (2170 U/ml) were positive before treatment. After chemotherapy with mFOLFOX6 + bevacizumab (B-mab), CEA and CA19-9 decreased to the normal range. However, serum p53 antibody titer remained positive (283 U/ml). After low anterior resection, the serum p53 antibody titer still remained positive (63.4 U/ml). Serum p53 antibody titer significantly changed and was associated with treatment response and tumor recurrence. In the last 6 months of the patient’s life, serum p53 antibody titer gradually decreased, which possibly reflects the modification of the patient’s immune response to p53 antigens.

Keywords

Serum p53 antibody Rectal cancer Liver metastases Lung metastases 

Notes

Compliance with ethical standards

Conflict of Interest:

Hideaki Shimada received research Grant from Medical and Biological Laboratories, co. ltd. The other co-authors declare that they have no conflict of interest.

Human/Animal Rights:

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments.

Informed Consent:

Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by task force of Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Shimada H, Ochiai T, Nomura F, Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multi-institutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang J, Xu Z, Yu L, Chen M, Li K, et al. Assessment of the potential diagnostic value of serum p53 antibody for cancer: a meta-analysis. PLoS One. 2014;9:e99255. doi: 10.1371/journal.pone.0099255.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Yamaguchi T, Takii Y, Maruyama S. Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients. Surg Today. 2014;44:1529–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Ochiai H, Ohishi T, Osumi K, Tokuyama J, Urakami H, Seki S, et al. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today. 2012;42:164–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Takeda A, Shimada H, Nakajima K, et al. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int J Clin Oncol. 2001;6:45–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2000;132:41–7.CrossRefGoogle Scholar
  8. 8.
    Tang R, Yeh CY, Wang JY, et al. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Ann Surg Oncol. 2009;16:2516–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Kawahara H, Watanabe K, Enomoto H, et al. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer. Anticancer Res. 2013;33:2221–5.PubMedGoogle Scholar
  10. 10.
    Shimada H, Okazumi S, Takeda A, Nabeya Y, Matsubara H, Funami Y, et al. Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg Today. 2001;31:591–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Shimada H, Shiratori T, Takeda A, Matsushita K, Okazumi S, Akutsu Y, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Lechpammer M, Lukac J, Lechpammer S, Kovacević D, Loda M, Kusić Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis. 2004;19:114–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Shimada H, Nagata M, Nabeya Y, et al. Paradoxical changing of serum p53 antibody titers during chemotherapy for a stage IV esophageal squamous cell carcinoma. Int Canc Conf J. 2014;44:1957–61.Google Scholar

Copyright information

© Japanese Society of Gastroenterology 2016

Authors and Affiliations

  • Takayuki Suzuki
    • 1
  • Hideaki Shimada
    • 1
    Email author
  • Mitsunori Ushigome
    • 1
  • Junichi Koike
    • 1
  • Kimihiko Funahashi
    • 1
  • Tetsuo Nemoto
    • 2
  • Hironori Kaneko
    • 1
  1. 1.Department of Surgery, School of MedicineToho UniversityTokyoJapan
  2. 2.Department of PathologyToho University School of MedicineTokyoJapan

Personalised recommendations